| Literature DB >> 35275557 |
Marle M Van Hienen1, Roy Kuiper1, Huub A M Middelkoop1,2, Jacobus J Van Hilten1, Maria Fiorella Contarino1,3, Victor J Geraedts1,4.
Abstract
BACKGROUND: Caregivers of Parkinson's disease (PD) patients provide important support during the pre- and postoperative phase of deep brain stimulation (DBS). High levels of caregiver burden have been reported after DBS. However, a comparison between preoperative and postoperative burden and associated factors has been insufficiently studied.Entities:
Keywords: Parkinson’s disease; caregiver burden; deep brain stimulation; epidemiologyzzm321990; quality of life
Mesh:
Year: 2022 PMID: 35275557 PMCID: PMC9484085 DOI: 10.3233/JPD-213093
Source DB: PubMed Journal: J Parkinsons Dis ISSN: 1877-7171 Impact factor: 5.520
Population characteristics
| Screening ( | Follow-up ( |
| |
| Age caregivera | 61.5 (52.25, 69.75) | 63 (61, 69) | 0.321 |
| Sex caregiver, femaleb | 70.8% (17) | 73.9% (17) | 0.813 |
| Relationship caregiverb | 0.158 | ||
| | 91.7% (22) | 87% (20) | |
| | 8.3% (2) | 0% (0) | |
| | 0% (0) | 4.3% (1) | |
| | 0% (0) | 8.7% (2) | |
| ZBI-12a | 9.50 (3.25, 16.75) | 6 (4, 14) | 0.709 |
| | 25% (6) | 13% (3) | 0.298 |
| Age patienta | 64 (53.5, 68) | 66 (57, 68) | 0.631 |
| Sex patientb, female | 37.5% (9) | 30.4% (7) | 0.609 |
| Disease durationa | 6.05 (5.25, 8.625) | 7.7 (6.7, 11) | 0.095 |
| MDS-UPDRS IIIc | |||
| | 18.33 (7.93) | 21.29 (12.39) | 0.340 |
| | 39.88 (8.49) | 49.41 (15.38) | 0.012 |
| | – | 32.52 (12.30) | – |
| MDS-UPDRS IVc | 10.05 (3.15) | 4.91 (4.93) | > 0.001 |
| PASc | 12.33 (7.53) | 7.87 (8.01) | 0.055 |
| ASa | 11 (9, 13) | 11.50 (9, 14.5) | 0.444 |
| SCOPA-AUTc | 18.58 (9.28) | 13.13 (6.25) | 0.023 |
| MoCAa | 26 (25, 28) | 26 (25, 28) | 0.905 |
| BDI-IIa | 15.5 (10.5, 20.75) | 7 (4, 12) | 0.001 |
| QUIP-RSa | 11.50 (2.25, 17.75) | 1 (0, 12) | 0.032 |
| FOGc | 5.91 (5.49) | 5.14 (4.65) | 0.612 |
| QoL patient | |||
| | 47.79 (22.32) | 31.61 (23.36) | 0.019 |
| | 10.08 (2.78) | 8.57 (2.39) | 0.051 |
| SCOPA Sleep | |||
| | 7.00 (3.74) | 4.30 (3.52) | 0.015 |
| | 4.96 (3.62) | 4.39 (2.94) | 0.559 |
| Overall sleep qualityb | 0.144 | ||
| | 0% (0) | 26.1% (6) | |
| | 8.7% (2) | 17.4% (4) | |
| | 21.7% (5) | 17.4% (4) | |
| | 26.1% (6) | 17.4% (4) | |
| | 26.1% (6) | 17.4% (4) | |
| | 13% (3) | 4.3% (1) | |
| | 4.3% (1) | 0% (0) |
aMann-Whitney U test, Median (25% IQR, 75% IQR). bChi-square test, % (N). cUnpaired T-test, Mean (±SD). *The ON situation was defined as 1.2 times the patients’ early morning dose at time of screening. At time of follow-up, the ON situation was defined as both 1.2 times the patients’ early morning dose and activate DBS device. **The OFF situation was defined as at least 12 hours absence of anti-parkinsonian medication at time of screening. At time of follow-up, the OFF situation was defined as both 12 hours absence of anti-parkinsonian medication and DBS device was switched off. +Caregiver overload≥17. ++NSP≥7. +++EDS≥5. ZBI-12, 12-item Zarit Burden Interview; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; PAS, Parkinson Anxiety Scale; AS, Apathy Scale; SCOPA-AUT, Scales for Outcome in Parkinson’s Disease – Autonomic Dysfunction; BDI-II, Beck Depression Inventory II; QUIP-RS, Questionnaire for Impulsive-Compulsive disorders in Parkinson’s Disease – Rating Scale; FOG, Freezing of Gait questionnaire; MoCA, Montreal Cognitive Assessment; PDQ-39, 39-item Parkinson’s Disease Questionnaire; EQ-5D, five dimension EuroQoL; SCOPA-Sleep, Scales for Outcome in Parkinson’s Disease – Sleep; NSP, Nighttime Sleeping Problems; EDS, Excessive Daytime Sleeping.
Effect of (univariate) patient-related covariates on caregiver burden
| Screening | Follow-up | Combined | ||||
|
| 95% CI |
| 95% CI |
| 95% CI | |
| Patients’ age | –0.071 | –0.382, 0.241 | –0.107 | –0.572, 0.358 | –0.085 | –0.334, 0.164 |
| Disease duration | –0.143 | –0.527, 0.241 | 0.078 | –0.943, 1.098 | –0.111 | –0.452, 0.231 |
| MDS-UPDRS III ‘ON’* | 0.246 | –0.168, 0.660 | 0.229 | –0.084, 0.542 | 0.229 | –0.001, 0.459 |
| MDS-UPDRS III ‘OFF’** | 0.298 | –0.080, 0.675 | 0.093 | –0.163, 0.349 | 0.113 | –0.070, 0.297 |
| MDS-UPDRS IV | –0.200 | –1.440, 1.040 | 0.158 | –0.632, 0.947 | 0.051 | –0.480, 0.581 |
| BDI-II | 0.599 | 0.201, 0.997 | 0.985 | 0.521, 1.448 | 0.603 | 0.334, 0.873 |
| PAS | 0.475 | 0.076, 0.874 | 0.546 | 0.138, 0.955 | 0.482 | 0.220, 0.743 |
| SCOPA-AUT | 0.308 | –0.031, 0.648 | 0.176 | –0.431, 0.783 | 0.251 | –0.027, 0.528 |
| SCOPA-Sleep | 0.584 | –0.286, 1.453 | 0.950 | –0.047, 1.947 | 0.684 | 0.097, 1.271 |
| PDQ-39 | 0.208 | 0.087, 0.329 | 0.242 | 0.121, 0.363 | 0.203 | 0.125, 0.282 |
| EQ-5D | 1.256 | 0.169, 2.343 | 2.249 | 1.017, 3.482 | 1.561 | 0.802, 2.321 |
| MoCA | –0.014 | –1.756, 1.727 | 0.159 | –1.270, 1.587 | 0.097 | –0.941, 1.135 |
| QUIP-RS | 0.424 | 0.118, 0.729 | 0.013 | –0.437, 0.464 | 0.223 | –0.026, 0.472 |
| AS | 0.574 | –0.425, 1.572 | 1.097 | 0.467, 1.727 | 0.920 | 0.417, 1.422 |
| FOG | 0.249 | –0.391, 0.888 | 1.333 | 0.736, 1.929 | 0.689 | 0.242, 1.136 |
*The ON situation was defined as 1.2 times the patients’ early morning dose at time of screening. At time of follow-up, the ON situation was defined as both 1.2 times the patients’ early morning dose and activate DBS device. **The OFF situation was defined as at least 12 hours absence of anti-parkinsonian medication at time of screening. At time of follow-up, the OFF situation was defined as both 12 hours absence of anti-parkinsonian medication and DBS device was switched off. MDS-UPDRS, Movement Disorder Society – Unified Parkinson’s Disease Rating Scale; BDI-II, Beck Depression Inventory II; PAS, Parkinson Anxiety Scale; SCOPA-AUT, Scales for Outcome in Parkinson’s Disease – Autonomic Dysfunction; SCOPA-Sleep, Scales for Outcome in Parkinson’s Disease – Sleep; PDQ-39, 39-item Parkinson’s Disease Questionnaire; EQ-5D, five dimension EuroQoL; MoCA, Montreal Cognitive Assessment; QUIP-RS, Questionnaire for Impulsive-Compulsive disorders in Parkinson’s Disease – Rating Scale; AS, Apathy Scale; FOG, Freezing of Gait questionnaire.
Multivariable regression analysis model
| Questionnaire |
|
| 95% CI | R2 |
| PDQ-39 | 0.095 | 0.210 | –0.056, 0.246 | 0.496 |
| BDI-II | 0.268 | 0.217 | –0.166, 0.702 | |
| AS | 0.641 | 0.014 | 0.139, 1.144 | |
| FOG | 0.008 | 0.974 | –0.468, 0.483 |
Constant: B = – 5.503; p = 0.069; 95% CI = – 11.459 – 0.452. PDQ-39, 39-item Parkinson’s Disease Questionnaire; BDI-II, Beck Depression Inventory II; AS, Apathy Scale; FOG, Freezing of Gait Questionnaire.